Roche obesity therapy leads to ~19% weight loss in Phase 1 trial

seekingalpha05-16

Roche (OTCQX:RHHBY) announced Thursday that its gut-hormone-mimicking obesity therapy, CT-388, caused 18.8% of weight loss on average over 24 weeks compared to placebo in a Phase 1 trial for healthy ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2435673237?lang=en_US&edition=fundamental","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1181551537/image_1181551537.jpg","is_english":true,"pubTime":"2024-05-16 18:48","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2435673237","market":"sg","top_or_hot":-1,"title":"Roche obesity therapy leads to ~19% weight loss in Phase 1 trial","media":"seekingalpha","content":"<div>\n<p>Roche (OTCQX:RHHBY) announced Thursday that its gut-hormone-mimicking obesity therapy, CT-388, caused 18.8% of weight loss on average over 24 weeks compared to placebo in a Phase 1 trial for healthy ...</p>\n\n<a href=\"https://seekingalpha.com/news/4107185-roche-obesity-therapy-causes-19-weight-loss\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Roche obesity therapy leads to ~19% weight loss in Phase 1 trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRoche obesity therapy leads to ~19% weight loss in Phase 1 trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-05-16 18:48 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4107185-roche-obesity-therapy-causes-19-weight-loss><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Roche (OTCQX:RHHBY) announced Thursday that its gut-hormone-mimicking obesity therapy, CT-388, caused 18.8% of weight loss on average over 24 weeks compared to placebo in a Phase 1 trial for healthy ...</p>\n\n<a href=\"https://seekingalpha.com/news/4107185-roche-obesity-therapy-causes-19-weight-loss\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0114720955.EUR","symbol_name":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","start_time":0,"source_url":"https://seekingalpha.com/news/4107185-roche-obesity-therapy-causes-19-weight-loss","article_id":"2435673237","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1181551537/image_1181551537.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2435673237","pubTimestamp":1715856519,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Roche (OTCQX:RHHBY) announced Thursday that its gut-hormone-mimicking obesity therapy, CT-388, caused 18.8% of weight loss on average over 24 weeks compared to placebo in a Phase 1 trial for healthy a","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU2491049909.HKD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (HKD) ACC","SG9999003800.SGD":"Nikko AM Global Dividend Equity Acc SGD-H","NVO.AU":"NOVO RESOURCES CORP-CDI","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","LU1267930730.SGD":"富兰克林美国机遇基金AS Acc SGD (CPF)","LU0109391861.USD":"富兰克林美国机遇基金A Acc","LU2491050071.SGD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (SGDHDG) ACC","LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD","LU1988902786.USD":"FULLERTON LUX FUNDS GLOBAL ABSOLUTE ALPHA \"I\" (USD) ACC","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","LU2491050154.USD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (USD) ACC","LU0079474960.USD":"联博美国增长基金A","LU2237443549.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA SGD-H","LU1551013342.USD":"Allianz Income and Growth Cl AMg2 DIS USD","03165":"华夏欧优股对冲","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","RHHBF":"Roche Holding Ltd","LU0640476718.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQ \"AU\" (USD) ACC","NVO":"诺和诺德","BK4139":"生物科技","RHHBY":"罗氏控股","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","LU2237443978.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc SGD-H","PFE":"辉瑞","PFE.AU":"PANTERA MINERALS LTD","LU1804176565.USD":"EASTSPRING INV GLOBAL GROWTH EQUITY \"A\" (USD) ACC","SG9999002224.SGD":"Allianz Global High Payout SGD","LU2237438978.USD":"Amundi Funds US Pioneer A2 (C) USD","LU0058720904.USD":"联博国际健康护理基金A","LU2264538146.SGD":"Fullerton Lux Funds - Global Absolute Alpha A Acc SGD","LLY":"礼来","AZN":"阿斯利康","BK4588":"碎股","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU0466842654.USD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"A\" (USD) ACC","BK7095":"多种金属与采矿","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","LU0122379950.USD":"贝莱德世界健康科学A2","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","BK4581":"高盛持仓","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","AMGN":"安进","LU0708995401.HKD":"FRANKLIN U.S. OPPORTUNITIES \"A\" (HKD) ACC","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU1551013425.SGD":"Allianz Income and Growth Cl AMg2 DIS H2-SGD","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC"},"translate_title":"罗氏肥胖疗法在1期试验中导致约19%的体重减轻","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AMGN":1,"NVO":1,"NVO.AU":1,"LLY":1,"PFE":1,"PFE.AU":1,"RHHBF":1,"AZN":1,"RHHBY":1,"03165":0.6},"content_text":"Roche (OTCQX:RHHBY) announced Thursday that its gut-hormone-mimicking obesity therapy, CT-388, caused 18.8% of weight loss on average over 24 weeks compared to placebo in a Phase 1 trial for healthy adults with obesity. The results were clinically meaningful and statistically significant, the Swiss drugmaker added. The results were clinically meaningful and statistically significant, the Swiss drugmaker added. Roche (OTCQX:RHHBF) added CT-388 into its pipeline with its $2.7B acquisition of Berkeley, California-based biotech Carmot Therapeutics this year. Detailed data indicate that the once-weekly subcutaneous injectable led to more than 5% weight loss in all trial participants who received the therapy, while 85%, 70%, and 45% of them achieved over 10%, 15%, and 20% weight loss over the duration, respectively. Notably, the trial subjects who were prediabetic at the start of the study indicated normal blood glucose levels after receiving CT-388, while the prediabetic individuals in the placebo group showed a largely unchanged blood glucose level. “The results are highly encouraging for further development of CT-388 for both obesity and type 2 diabetes and underscore its potential to become a best-in-class therapy with durable weight loss and glucose control,” Roche’s (OTCQX:RHHBF) medical chief Levi Garraway remarked. The dual GLP-1/GIP receptor agonist demonstrated mild to moderate gastrointestinal-related adverse events, similar to incretin-based medicines such as FDA-approved weight loss therapies Wegovy and Zepbound from Novo Nordisk (NVO) and Eli Lilly (LLY). Roche (OTCQX:RHHBF) expects to share additional data from the study in H2 2024. That readout will represent those who were obese with type 2 diabetes and received 12 weeks of therapy.  Other leading drugmakers with weight-loss therapies in their pipelines include Amgen (AMGN), Pfizer (PFE), and AstraZeneca (AZN).","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.5","shortVersion":"4.22.5","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2435673237"}